Birinapant - Medivir AB
Alternative Names: IGM-9427; TL-32711Latest Information Update: 28 Feb 2023
At a glance
- Originator Princeton University
- Developer IGM Biosciences; Medivir AB; National Cancer Institute (USA); University of Pennsylvania
- Class Amides; Antineoplastics; Antivirals; Indoles; Pyrrolidines; Small molecules
- Mechanism of Action Apoptosis stimulants; Inhibitor of apoptosis protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Chronic myelomonocytic leukaemia; Colorectal cancer; Myelodysplastic syndromes; Ovarian cancer; Solid tumours
- Phase I/II Acute myeloid leukaemia; Hepatitis B; Precursor cell lymphoblastic leukaemia-lymphoma
- Phase I Non-Hodgkin's lymphoma
- No development reported Head and neck cancer; HIV infections; Legionella infections; Lymphoma; Pancreatic cancer; Tuberculosis
Most Recent Events
- 28 Feb 2023 No recent reports of development identified for phase-I development in Head-and-neck-cancer(Combination therapy, Recurrent, Second-line therapy or greater) in USA (IV)
- 04 Nov 2021 Phase-I clinical trials in Non-Hodgkin's lymphoma (Combination therapy, Second-line therapy or greater, Late-stage disease, Metastatic disease) in USA (IV) (NCT04553692)
- 04 Nov 2021 Phase-I clinical trials in Solid tumours (Combination therapy, Second-line therapy or greater, Late-stage disease, Metastatic disease) in USA (IV) (NCT04553692)